Arbutus Biopharma Corporation (ABUS:NASDAQ) closed at $4.06 on November 4, 2026, up 4.64% on the day. The stock trades 25.5% below its 52-week high of $5.45 and 16.0% above its 52-week low of $3.50. Over the past year, it lost 11.9%. Arbutus Biopharma Corporation is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 4, 2025, ABUS closed higher on 119 days (47%). Its best day was August 21, 2026 (+9.22%) and its worst was January 16, 2026 (-13.62%). The stock moved 10% or more in a single session 1 time.
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also comprise ARB-1740, a pan-genotypic second-generation siRNA therapeutic in Phase II multi-dose study in Hepatitis B e antigen-chronic HBV patients; and AB-423, a core protein/capsid assembly inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates, including oral surface antigen inhibitors, cccDNA targeting agents, and immunomodulators. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patie...
Find more stocks like ABUS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.